Ceres loses $9.3M, missing estimates
Thousand Oaks-based agricultural biotech firm Ceres’ third-quarter net loss widened to $9.3 million, or 38 cents per share, on revenue of $1.4 million, it said July 11. The energy crop firm attributed the higher loss to added expenses from expanding business operations in Brazil and higher-than-expected variability in how much fuel its crops can produce. Read More →
Amgen news kicks off Q3 trading: CalAmp frontrunner in first-half standings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Under pressure to sell itself, Vitesse plans $30M stock offering
Shares of Camarillo-based Vitesse Semiconductor Corp. were down 15 percent to $2.30 in mid-day trading June 19 as the company announced a public stock offering to raise up to $30 million. The move comes as the company faces pressure from Columbia Pacific Advisors, an investment firm that owns nearly 10 percent of Vitesse, to sell Read More →
Dole CEO offers $1.1 billion to take firm private
Westlake Village-based Dole Food Co.’s stock soared more than 21 percent Tuesday morning as CEO David Murdock made a cash offer of $12 a share for the 60 percent of the company he doesn’t own in a deal valued at $1.1 billion. Dole is one of the biggest producers and importers of fresh fruit and Read More →
Amgen teams up for Chinese joint venture
Thousand Oaks-based biotech giant Amgen has teamed up with a Chinese company for a joint venture to sell its colorectal cancer drug Vectibix there. Zhejiang Beta Pharma will be 51 percent owner of the the new firm, which will be known as Amgen-Beta Pharmaceuticals. The deal is still subject to approval from Chinese authorities. Amgen’s Read More →
